Lausanne, Switzerland
ADC Therapeutics, based in Switzerland, is a commercial-stage global leader in antibody drug conjugates (ADCs), dedicated to transforming cancer treatment. Founded in 2011, the company's expertise spans clinical development to manufacturing. With a focus on pioneering the ADC sector, their approved and marketed product, ZYNLONTA® (loncastuximab tesirine-lpyl), has achieved accelerated approval from the FDA and conditional approval from the European Commission for treating diffuse large B-cell lymphoma.
Their innovation extends to developing a next-generation PSMA-targeting ADC, showcasing a robust pipeline. Recently securing a $60.00M private placement from investors like Redmile Group and TCGX, ADC Therapeutics is strategically positioning itself for continued growth in the Biopharma and Biotechnology industries.
